Riaz Bandali joins the iia board

The iia is pleased to announce that Riaz Bandali has been appointed to the board of the International Irradiation Association. 

Riaz is currently the President of Nordion (Canada) Inc. and member of the Sotera Health Executive Committee. 

Prior to joining Nordion, Riaz served as the President & CEO of Emerald Health Therapeutics and previously as Co-Chair of the Pure Sun Farms Board of Directors. He has also served as President of Early Stage and Translation Sciences at Syneos Health, a top 3 global Clinical Research Organization (CRO), from 2010 to 2019, and as its Chief Innovation Officer in 2017. Prior to his role with Syneos Health, Riaz also held several executive positions, with global operations, strategy, M&A and P&L oversight, at Inventiv Health, Sciex (a Danaher Company) and several business units within MDS. Riaz stated his career in Venture Capital as an investment analyst and, ultimately, as a Vice President and Venture Partner with MDS Capital.  

Riaz holds a Bachelor of Science Degree from the University of British Columbia, an MBA from McGill University and he has completed the Advanced Management Program at Harvard Business School. 

Riaz has served on the boards of several private and public health and life sciences, as well as biotechnology companies, in Canada and the United States.   

The iia is now delighted to welcome Riaz and his wealth of experience to the iia board and very much looks forward to working with him as the Association enters a new phase in its evolution.